Tet-pLKO-puro-SOX2 Citations (2)

Originally described in: Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.
Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, Rivers CS, Foo CK, Bhatt D, Stinson J, Gnad F, Haverty PM, Gentleman R, Chaudhuri S, Janakiraman V, Jaiswal BS, Parikh C, Yuan W, Zhang Z, Koeppen H, Wu TD, Stern HM, Yauch RL, Huffman KE, Paskulin DD, Illei PB, Varella-Garcia M, Gazdar AF, de Sauvage FJ, Bourgon R, Minna JD, Brock MV, Seshagiri S Nat Genet. 2012 Oct;44(10):1111-6. doi: 10.1038/ng.2405. Epub 2012 Sep 2. PubMed Journal

---

Articles Citing Tet-pLKO-puro-SOX2

Articles
SOX2 Expression and Transcriptional Activity Identifies a Subpopulation of Cancer Stem Cells in Sarcoma with Prognostic Implications. Menendez ST, Rey V, Martinez-Cruzado L, Gonzalez MV, Morales-Molina A, Santos L, Blanco V, Alvarez C, Estupinan O, Allonca E, Rodrigo JP, Garcia-Castro J, Garcia-Pedrero JM, Rodriguez R. Cancers (Basel). 2020 Apr 13;12(4). pii: cancers12040964. doi: 10.3390/cancers12040964. PubMed
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer. Phoenix JT, Budreika A, Schmeck DA, Kostlan RJ, Ferrari MG, Young KS, Rogers CS, Deegan CD, Bienko MW, Bergom HE, Boytim E, Brown RM, Walewicz JA, Bhagi SK, Ellis L, Antonarakis ES, Drake JM, Bawa PS, Vellky JE, Williams A, Rezine NM, Rennhack JP, Fanning SW, Hwang JH, Szmulewitz RZ, Vander Griend DJ, Kregel S. bioRxiv [Preprint]. 2025 Jul 19:2025.07.18.664790. doi: 10.1101/2025.07.18.664790. PubMed

If you have published an article using this material, please email us at to have your article added to this page.